ziltivekimab
Coverage of ziltivekimab in the Nexus archive.
- Novo Nordisk stock sinks after anti-inflammatory heart drug fails late-stage trial
Novo Nordisk stock declined following the failure of its experimental anti-inflammatory drug ziltivekimab in a late-stage trial. The drug did not reduce major adverse cardiovascular events compared to a placebo in a study involving over 6,300 patients.
- STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
Novo Nordisk's investigational drug ziltivekimab failed to reduce major heart events in a Phase 3 trial involving over 6,300 participants with heart disease, kidney disease, and inflammation, despite lowering inflammation markers. The company's shares fell about 7% following the announcement.
- Novo Nordisk shares dive after heart medicine fails trial
Novo Nordisk shares declined after the experimental heart medicine ziltivekimab failed to demonstrate a statistically significant reduction in major cardiovascular adverse events. The company announced the trial results, which did not meet its primary endpoint.